Organon与三星Bioepis已就扩大合作协议达成一致，旨在加拿大市场共同商业化生物类似药Pyzchiva®（乌司奴单抗）。该药物参照原研药Stelara®（乌司奴单抗）开发。
此次协议扩展标志着双方在生物类似药领域合作的深化，旨在为加拿大患者提供更多治疗选择。Pyzchiva®作为Stelara®的生物类似药，其商业化进程的推进有望在相关治疗领域引入新的竞争。
通过合作，双方将整合资源与专长，加速该产品在加拿大市场的准入与推广。此举不仅强化了Organon在生物类似药领域的布局，也体现了三星Bioepis在生物制剂开发方面的持续投入。
随着协议范围的扩大，双方期待能更有效地满足加拿大医疗市场的需求，并为医疗系统带来潜在的成本效益。未来进展将取决于监管审批与市场实际接受情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.